|
1
|
Takano A, Oriuchi N, Tsushima Y,
Taketomi-Takahashi A, Nakajima T, Arisaka Y, Higuchi T, Amanuma M
and Endo K: Detection of metastatic lesions from malignant
pheochromocytoma and paraganglioma with diffusion-weighted magnetic
resonance imaging: Comparison with 18F-FDG positron emission
tomography and 123I-MIBG scintigraphy. Ann Nucl Med. 22:395–401.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brandi ML, Gagel RF, Angeli A, Bilezikian
JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG,
Libroia A, et al: Guidelines for diagnosis and therapy of MEN type
1 and type 2. J Clin Endocrinol Metab. 86:5658–5671. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sherman SI, Brierley JD, Sperling M, Ain
KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, et
al: Initial analysis of staging and outcomes from a prospective
multicenter study of treatment of thyroid carcinoma. Thyroid.
83:1012–1021. 1998.
|
|
4
|
Lawrence B, Gustafsson BI, Chan A, Svejda
B, Kidd M and Modlin IM: The epidemiology of gastroenteropancreatic
neuroendocrine tumors. Endocrinol Metab Clin North Am. 40:1–18.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Washington MK, Tang LH, Berlin J, Branton
PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL,
Jessup JM, et al: Protocol for the examination of specimens from
patients with neuroendocrine tumors (carcinoid tumors) of the small
intestine and ampulla. Arch Pathol Lab Med. 134:181–186.
2010.PubMed/NCBI
|
|
6
|
Heymann MF, Joubert M, Nemeth J, Franc B,
Visset J, Hamy A, le Borgne J, le Neel JC, Murat A, Cordel S, et
al: Prognostic and immunohistochemical validation of the capella
classification of pancreatic neuroendocrine tumours: An analysis of
82 sporadic cases. Histopathology. 36:421–432. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Basturk O, Yang Z, Tang LH, Hruban RH,
Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, et
al: The high-grade (WHO G3) pancreatic neuroendocrine tumor
category is morphologically and biologically heterogenous and
includes both well differentiated and poorly differentiated
neoplasms. Am J Surg Pathol. 39:683–690. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Strosberg JR, Cheema A, Weber J, Han G,
Coppola D and Kvols LK: Prognostic relevance of a novel American
Joint Committee on Cancer staging classification for neuroendocrine
tumors of the pancreas. J Clin Oncol. 29:3044–3049. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jann H, Roll S, Couvelard A, Hentic O,
Pavel M, Müller-Nordhorn J, Koch M, Röcken C, Rindi G, Ruszniewski
P, et al: Neuroendocrine tumors of midgut and hindgut origin:
Tumor-node-metastasis classification determines clinical outcome.
Cancer. 117:3332–3341. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pape UF, Jann H, Müller-Nordhorn J,
Bockelbrink A, Berndt U, Willich SN, Koch M, Röcken C, Rindi G and
Wiedenmann B: Prognostic relevance of a novel TNM classification
system for upper gastroenteropancreatic neuroendocrine tumors.
Cancer. 113:256–265. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Przygodzki RM, Finkelstein SD, Langer JC,
Swalsky PA, Fishback N, Bakker A, Guinee DG, Koss M and Travis WD:
Analysis of p53, K-ras-2 and C-raf-1 in pulmonary neuroendocrine
tumors. Correlation with histological subtype and clinical outcome.
Am J Pathol. 148:1531–1541. 1996.PubMed/NCBI
|
|
12
|
Travis WD, Rush W, Flieder DB, Falk R,
Fleming MV, Gal AA and Koss MN: Survival analysis of 200 pulmonary
neuroendocrine tumors with clarification of criteria for atypical
carcinoid and its separation from typical carcinoid. Am J Surg
Pathol. 22:934–944. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fink G, Krelbaum T, Yellin A, Bendayan D,
Saute M, Glazer M and Kramer MR: Pulmonary carcinoid: Presentation,
diagnosis, and outcome in 142 cases in Israel and review of 640
cases from the literature. Chest. 119:1647–1651. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Srivastava A and Hornick JL:
Immunohistochemical staining for CDX-2, PDX-1, NESP-55 and TTF-1
can help distinguish gastrointestinal carcinoid tumors from
pancreatic endocrine and pulmonary carcinoid tumors. Am J Surg
Pathol. 33:626–632. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cardillo G, Sera F, Di Martino M, Graziano
P, Giunti R, Carbone L, Facciolo F and Martelli M: Bronchial
carcinoid tumors: Nodal status and long-term survival after
resection. Ann Thorac Surg. 77:1781–1785. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Okike N, Bernatz PE and Woolner LB:
Carcinoid tumors of the lung. Ann Thorac Surg. 22:270–275. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moran CA, Suster S, Coppola D and Wick MR:
Neuroendocrine carcinomas of the lung: A critical analysis. Am J
Clin Pathol. 131:206–221. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wollina U, Langer D and Tchernev G:
Mushroom-like skin tumours: Report of three cases. Open Access
Maced J Med Sci. 5:515–517. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gerer KF, Erdmann M, Hadrup SR, Lyngaa R,
Martin LM, Voll RE, Schuler-Thurner B, Schuler G, Schaft N, Hoyer S
and Dörrie J: Preclinical evaluation of NF-κB-triggered dendritic
cells expressing the viral oncogenic driver of Merkel cell
carcinoma for therapeutic vaccination. The Adv Med Oncol.
9:451–464. 2017. View Article : Google Scholar
|
|
20
|
Sauer CM, Haugg AM, Chteinberg E,
Rennspiess D, Winnepenninckx V, Speel EJ, Becker JC, Kurz AK and
Zur Hausen A: Reviewing the current evidence supporting early
B-cells as the cellular origin of Merkel cell carcinoma. Crit Rev
Oncol Hematol. 116:99–105. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Murakami I, Takata K, Matsushita M, Nonaka
D, Iwasaki T, Kuwamoto S, Kato M, Mohri T, Nagata K, Kitamura Y, et
al: Immunoglobulin expressions are only associated with
MCPyV-positive Merkel cell carcinomas but not with MCPyV-negative
ones: Comparison of prognosis. Am J Surg Pathol. 38:1627–1635.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kulke MH, Siu LL, Tepper JE, Fisher G,
Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday
TJ, et al: Future directions in the treatment of neuroendocrine
tumors: Consensus report of the National Cancer Institute
Neuroendocrine Tumor clinical trials planning meeting. J Clin
Oncol. 29:934–943. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mosquera C, Koutlas NJ and Fitzgerald TL:
Localized high-grade gastroenteropancreatic neuroendocrine tumors:
Defining prognostic and therapeutic factors for a disease of
increasing clinical significance. Eur J Surg Oncol. 42:1471–1477.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim JY and Hong SM: Recent updates on
neuroendocrine tumors from the gastrointestinal and
pancreatobiliary Tracts. Arch Pathol Lab Med. 140:437–448. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schindl M, Kaczirek K, Kaserer K and
Niederle B: Is the new classification of neuroendocrine pancreatic
tumors of clinical help? World J Surg. 24:1312–1318. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yao JC, Hassan M, Phan A, Dagohoy C, Leary
C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A and Evans
DB: One hundred years after ‘carcinoid’: Epidemiology of and
prognostic factors for neuroendocrine tumors in 35,825 cases in the
United States. J Clin Oncol. 26:3063–3072. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vinik AI and Renar IP: Neuroendocrine
tumors of carcinoid varietyEndocrinology. De Grool L: WB Saunders;
Philadelphia, PA: pp. 2803–2814. 1995, PubMed/NCBI
|
|
28
|
Oberg K and Castellano D: Current
knowledge on diagnosis and staging of neuroendocrine tumors. Cancer
Metastasis Rev. 30:3–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Klimstra DS, Modlin IR, Adsay NV, Chetty
R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, et
al: Pathology reporting of neuroendocrine tumors: Application of
the Delphic consensus process to the development of a minimum
pathology data set. Am J Surg Pathol. 34:300–313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Travis WB, Brambilla E, Muller-Hermelink
and Harris CC: Pathology and genetics of tumours of lung, pleura,
thymus and heart. IARC Press, Lyon. 10:1240–1242. 2004.
|
|
31
|
Klimstra DS, Modlin IR, Coppola D, Lloyd
RV and Suster S: The pathologic classification of neuroendocrine
tumors: A review of nomenclature, grading and staging system.
Pancreas. 39:707–712. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pelosi G, Volante M, Papotti M, Sonzogni
A, Masullo M and Viale G: Peptide receptors in neuroendocrine
tumors of the lung as potential radionuclide diagnosis and therapy.
Q J Nucl Med Mol Imaging. 50:272–287. 2006.PubMed/NCBI
|
|
33
|
Bosman FT: Neuroendocrine cells in
non-endocrine tumors: What does it mean? Ges Path. 81:62–72.
1996.
|
|
34
|
Cueto A, Burigana F, Nicolini A and
Lugnani F: Neuroendocrine tumors of the lung: Histological
classification, diagnosis, traditional and new therapeutic
approaches. Curr Med Chem. 21:1107–1116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kaltsas G, Androulakis II, de Herder WW
and Grossman AB: Paraneoplastic syndromes secondary to
neuroendocrine tumours. Endocr Relat Cancer. 17:R173–R193. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Keffer JH: Endocrinopathy and ectopic
hormones in malignancy. Hematol Oncol Clin North Am. 10:811–823.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bollanti L, Riondino G and Strollo F:
Endocrine paraneoplastic syndromes with special reference to the
elderly. Endocrine. 14:151–157. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hollander IJ and Aponte GE: Ectopic
hormone production by malignant tumors. Ann Clin Lab Sci.
9:268–274. 1979.PubMed/NCBI
|
|
39
|
Das S, Mukherjee K, Bhattacharya S and
Chowdhury JR: Ectopic production of placental hormones (human
chorionic gonadotropin and human placental lactogen) in carcinoma
of the uterine cervix. Cancer. 51:1854–1857. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mnif Feki M, Mnif F, Kamoun M, Charfi N,
Rekik N, Bennaceur B, Mnif L, Sellami Boudawara T and Abid M:
Ectopic secretion of GHRH by a pancreatic neuroendocrine tumor
associated with an empty sella. Ann Endocrinol (Paris). 72:522–525.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Glikson M, Gil-Ad I, Galun E, Dresner R,
Zilberman S, Halperin Y, Okon E, Laron Z and Rubinow A: Acromegaly
due to ectopic growth hormone-releasing hormone secretion by a
bronchial carcinoid tumour. Dynamic hormonal responses to various
stimuli. Acta Endocrinol (Copenh). 125:366–371. 1991.PubMed/NCBI
|
|
42
|
Garby L, Caron P, Claustrat F, Chanson P,
Tabarin A, Rohmer V, Arnault G, Bonnet F, Chabre O, Christin-Maitre
S, et al: Clinical characteristics and outcome of acromegaly
induced by ectopic secretion of growth hormone-releasing hormone
(GHRH): A French nationwide series of 21 cases. GTE Group. J Clin
Endocrinol Metab. 97:2093–2104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hubold C and Brabant G: Ectopic hormone
secretion by neuroendocrine tumors. Internist (Berl). 53:145–151.
2012.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Baylin SB and Mendelsohn G: Ectopic
(inappropriate) hormone production by tumors: Mechanisms involved
and the biological and clinical implications. Endocrin Rev.
1:45–77. 1980. View Article : Google Scholar
|
|
45
|
Yamasaki R, Saito H, Sano T, Kameyama K,
Yoshimoto K, Hosoi E, Matsumura M, Harada K and Saito S: Ectopic
growth hormone-releasing hormone (GHRH) syndrome in a case with
multiple endocrine neoplasia type I. Endocrinol Jpn. 35:97–109.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hochwald SN, Zee S, Conlon KC, Colleoni R,
Louie O, Brennan MF and Klimstra DS: Prognostic factors in
pancreatic endocrine neoplasms: An analysis of 136 cases with a
proposal for low-grade and intermediate-grade groups. J Clin Oncol.
20:2633–2642. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hoang MP, Hruban RH and Albores-Saavedra
J: Clear cell endocrine pancreatic tumor mimicking renal cell
carcinoma: A distinctive neoplasm of von Hippel-Lindau disease. Am
J Surg Pathol. 25:602–609. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Klöppel G, Perren A and Heitz PU: The
gastroenteropancreatic neuroendocrine cell system and its tumors:
The WHO classification. Ann N Y Acad Sci. 1014:13–27. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kamp K, Feelders RA, van Adrichem RC, de
Rijke YB, van Nederveen FH, Kwekkeboom DJ and de Herder WW:
Parathyroid hormone-related peptide (PTHrP) secretion by
gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Clinical
features, diagnosis, management, and follow-up. J Clin Endocrinol
Metab. 99:3060–3069. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Schally AV, Comaru-Schally AM, Nagy A,
Kovacs M, Szepeshazi K, Plonowski A, Varga JL and Halmos G:
Hypothalamic hormones and cancer. Front Neuroendocrinol.
22:248–291. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Szereday Z, Schally AV, Varga JL,
Kanashiro CA, Hebert F, Armatis P, Groot K, Szepeshazi K, Halmos G
and Busto R: Antagonists of growth hormone-releasing hormone
inhibit the proliferation of experimental non-small cell lung
carcinoma. Cancer Res. 63:7913–7919. 2003.PubMed/NCBI
|
|
52
|
Szepeshazi K, Schally AV, Groot K, Armatis
P, Hebert F and Halmos G: Antagonists of growth hormone-releasing
hormone (GH-RH) inhibit in vivo proliferation of experimental
pancreatic cancers and decrease IGF-II levels in tumours. Eur J
Cancer. 36:128–136. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Szepeshazi K, Block NL and Schally AV: The
use of peptide analogs for the treatment of gastrointestinal,
pancreatic, liver and urinary bladder cancers. Horm Mol Biol Clin
Investig. 1:103–110. 2010.PubMed/NCBI
|
|
54
|
Cidon EU: New therapeutic approaches to
metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse
into the future. World J Gastrointest Oncol. 9:4–20. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wolin EM: The expanding role of
somatostatin analogs in the management of neuroendocrine tumors.
Gastrointest Cancer Res. 5:161–168. 2012.PubMed/NCBI
|
|
56
|
Baldelli R, Barnabei A, Rizza L, Isidori
AM, Rota F, Di Giacinto P, Paoloni A, Torino F, Corsello SM, Lenzi
A and Appetecchia M: Somatostatin analogs therapy in
gastroenteropancreatic neuroendocrine tumors: Current aspects and
new perspectives. Front Endocrinol (Lausanne). 5:72014.PubMed/NCBI
|
|
57
|
Sidéris L, Dubé P and Rinke A: Antitumor
effects of somatostatin analogs in neuroendocrine tumors.
Oncologist. 17:747–755. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Boden G, Ryan IG, Eisenschmid BL, Shelmet
JJ and Owen OE: Treatment of inoperable glucagonoma with the
long-acting somatostatin analogue SMS 201–995. N Engl J Med.
314:1686–1689. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Vezzosi D, Bennet A, Rochaix P, Courbon F,
Selves J, Pradere B, Buscail L, Susini C and Caron P: Octreotide in
insulinoma patients: Efficacy on hypoglycemia, relationships with
Octreoscan scintigraphy and immunostaining with anti-sst2A and
anti-sst5 antibodies. Eur J Endocrinol. 152:757–67. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Pollak MN and Schally AV: Mechanisms of
antineoplastic action of somatostatin analogs. Proc Soc Exp Biol
Med. 217:pp. 143–152. 1998; View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Arnold R, Trautmann ME, Creutzfeldt W,
Benning R, Benning M, Neuhaus C, Jurgensen R, Stein K, Schafer H,
Bruns C, et al: Somatostatin analogue octreotide and inhibition of
tumour growth in metastatic endocrine gastroenteropancreatic
tumours. Gut. 38:430–438. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Oberg K, Krenning E, Sundin A, Bodei L,
Kidd M, Tesselaar M, Ambrosini V, Baum RP, Kulke M, Pavel M, et al:
Delphic consensus assessment: Imaging and biomarkers in
gastroenteropancreatic neuroendocrine tumor disease management.
Endocr Connect. 5:174–187. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Oberg K and Jelic S; ESMO Guidelines
Working Group, : Neuroendocrine gastroenteropancreatic tumors: ESMO
clinical recommendation for diagnosis, treatment and follow-up. Ann
Oncol. 20:150–153. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Qian ZR, Li T, Ter-Minassian M, Yang J,
Chan JA, Brais LK, Masugi Y, Thiaglingam A, Brooks N, Nishihara R,
et al: Association between somatostatin receptor expression and
clinical outcomes in neuroendocrine tumors. Pancreas. 45:1386–1393.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Bruns C, Lewis I, Briner U, Meno-Tetang G
and Weckbecker G: SOM230: A novel somatostatin peptidomimetic with
broad somatotropin release inhibiting factor (SRIF) receptor
binding and a unique antisecretory profile. Eur J Endocrinol.
146:707–716. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Capdevila J, Weber M and Pape UF:
Continued advances in targeting gastroenteropancreatic
neuroendocrine tumors: General discussion. Clin Adv Hematol oncol.
12(12 Suppl 19): S222014.
|
|
67
|
Jones S, Zhang X, Parsons DW, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et
al: Core signaling pathways in human pancreatic cancers revealed by
global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Fazio N, Abdel-Rahman O, Spada F, Galdy S,
De Dosso S, Capdevila J and Scarpa A: A RAF signaling in
neuroendocrine neoplasms: From bench to bedside. Cancer Treat Rev.
40:974–979. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Gómez K, Varghese J and Jiménez C:
Medullary thyroid carcinoma: Molecular signaling pathways and
emerging therapies. J Thyroid Res. 2011:8158262011. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Cristea S and Sage J: Is the canonical
RAF/MEK/ERK signaling pathway a therapeutic target in SCLC? J
Thorac Oncol. 11:1233–1241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Jochmanová I, Zelinka T, Widimský J Jr and
Pacak K: HIF signaling pathway in pheochromocytoma and other
neuroendocrine tumors. Physiol Res. 63 Suppl 2:S251–S262.
2014.PubMed/NCBI
|
|
72
|
Trobridge P, Knoblaugh S, Washington MK,
Munoz NM, Tsuchiya KD, Rojas A, Song X, Ulrich CM, Sasazuki T,
Shirasawa S and Grady WM: TGF-beta receptor inactivation and mutant
Kras induce intestinal neoplasms in mice via a
beta-catenin-independent pathway. Gastroenterology. 136:1680–1688.
e7. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Brambilla E and Gazdar A: Pathogenesis of
lung cancer signalling pathways: Roadmap for therapies. Eur Respir
J. 33:1485–1497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Vlotides G, Tanyeri A, Spampatti M,
Zitzmann K, Chourdakis M, Spttl C, Maurer J, Nölting S, Göke B and
Auernhammer CJ: Anticancer effects of metformin on neuroendocrine
tumor cells in vitro. Hormones Athens. 13:498–508. 2014.PubMed/NCBI
|
|
75
|
Chen Y, Nowak I, Huang J, Keng PC, Sun H,
Xu H, Wei G and Lee SO: Erk/MAP kinase signaling pathway and
neuroendocrine differentiation of non-small-cell lung cancer. J
Thorac Oncol. 9:50–58. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Sriuranpong V, Borges MW, Ravi RK, Arnold
DR, Nelkin BD, Baylin SB and Ball DW: Notch signaling induces cell
cycle arrest in small cell lung cancer cells. Cancer Res.
61:3200–3205. 2001.PubMed/NCBI
|
|
77
|
Lee HY, Chun KH, Liu B, Wiehle SA,
Cristiano RJ, Hong WK, Cohen P and Kurie JM: Insulin-like growth
factor binding protein-3 inhibits the growth of non-small cell lung
cancer. Cancer Res. 62:3530–3537. 2002.PubMed/NCBI
|
|
78
|
Cortez E, Gladh H, Braun S, Bocci M,
Cordero E, Björkström NK, Miyazaki H, Michael IP, Eriksson U,
Folestad E and Pietras K: Functional malignant cell heterogeneity
in pancreatic neuroendocrine tumors revealed by targeting of
PDGF-DD. Proc Natl Acad Sci USA. 113:pp. E864–E873. 2016;
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Kunnimalaiyaan M and Chen H: Tumor
suppressor role of Notch-1 signaling in neuroendocrine tumors.
Oncologist. 12:535–542. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Cakir M, Dworakowska D and Grossman A:
Somatostatin receptor biology in neuroendocrine and pituitary
tumours: Part 1-molecular pathways. J Cell Mol Med. 14:2570–2584.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zarebczan B and Chen H: Signaling
mechanisms in neuroendocrine tumors as targets for therapy.
Endocrinol Metab Clin North Am. 39:8018–8010. 2010. View Article : Google Scholar
|
|
82
|
de Groot JW, Links TP, Plukker JT, Lips CJ
and Hofstra RM: RET as a diagnostic and therapeutic target in
sporadic and hereditary endocrine tumors. Endocr Rev. 27:535–560.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Shen MM and Abate-Shen C: Molecular
genetics of prostate cancer: New prospects for old challenges.
Genes Dev. 24:1967–2000. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Younes N, Fulton N, Tanaka R, Wayne J,
Straus FH II and Kaplan EL: The presence of K-12 ras mutations in
duodenal adenocarcinomas and the absence of ras mutations in other
small bowel adenocarcinomas and carcinoid tumors. Cancer.
79:1804–1808. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ravi RK, Weber E, McMahon M, Williams JR,
Baylin S, Mal A, Harter ML, Dillehay LE, Claudio PP, Giordano A, et
al: Activated Raf-1 causes growth arrest in human small cell lung
cancer cells. J Clin Invest. 101:153–159. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Ravi R, Thiagalingam A, Weber E, McMahon
M, Nelkin BD and Mabry M: Raf-1 causes growth suppression and
alteration of neuroendocrine markers in DMS53 human small-cell lung
cancer cells. Am J Respir Cell Mol Biol. 20:543–549. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Sippel RS, Carpenter JE, Kunnimalaiyaan M,
Lagerholm S and Chen H: Raf-1 activation suppresses neuroendocrine
marker and hormone levels in human gastrointestinal carcinoid
cells. Am J Physiol Gastrointest Liver Physiol. 285:G245–G254.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Van Gompel J, Kunnimalaiyaan M, Holen K
and Chen H: ZM336372, a Raf-1 activator, suppresses growth and
neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer
Ther. 4:910–917. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Kim DH, Sarbassov DD, Ali SM, King JE,
Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM: mTOR
interacts with raptor to form a nutrient-sensitive complex that
signals to the cell growth machinery. Cell. 110:163–175. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Sancak Y, Thoreen CC, Peterson TR,
Lindquist RA, Kang SA, Spooner E, Carr SA and Sabatini DM: PRAS40
is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol
Cell. 25:903–915. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Villaume K, Blanc M, Gouysse G, Walter T,
Couderc C, Nejjari M, Vercherat C, Cordier-Bussat M, Roche C and
Scoazec JY: VEGF secretion by neuroendocrine tumor cells is
inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR
pathway. Neuroendocrinology. 91:268–278. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Couderc C, Poncet G, Villaume K, Blanc M,
Gadot N, Walter T, Lepinasse F, Hervieu V, Cordier-Bussat M and
Scoazec JY: Targeting the PI3K/mTOR pathway in murine endocrine
cell lines: In vitro and in vivo effects on tumor cell growth. Am J
Pathol. 178:336–344. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
94
|
Krystal GW, Sulanke G and Litz J:
Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks
growth, promotes apoptosis and enhances sensitivity of small cell
lung cancer cells to chemotherapy. Mol Cancer Ther. 1:913–922.
2002.PubMed/NCBI
|
|
95
|
Pitt S, Chen H and Kunnimalaiyaan M:
Inhibition of phosphatidylinositol 3-kinase/Akt signaling
suppresses tumor cell proliferation and neuroendocrine marker
expression in GI carcinoid tumors. Ann Surg Oncol. 16:2936–2942.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Hara K, Maruki Y, Long X, Yoshino K,
Oshiro N, Hidayat S, Tokunaga C, Avruch J and Yonezawa K: Raptor, a
binding partner of target of rapamycin (TOR), mediates TOR action.
Cell. 110:177–189. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Chan J and Kulke M: Targeting the mTOR
signaling pathway in neuroendocrine tumors. Curr Treat Options
Oncol. 15:365–379. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Cerovac V, Monteserin-Garcia J, Rubinfeld
H, Buchfelder M, Losa M, Florio T, Paez-Pereda M, Stalla GK and
Theodoropoulou M: The somatostatin analogue octreotide confers
sensitivity to rapamycin treatment on pituitary tumor cells. Cancer
Res. 70:666–674. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Nakakura EK, Sriuranpong VR,
Kunnimalaiyaan M, Hsiao EC, Schuebel KE, Borges MW, Jin N, Collins
BJ, Nelkin BD, Chen H and Ball DW: Regulation of neuroendocrine
differentiation in gastrointestinal carcinoid tumor cells by notch
signaling. J Clin Endocrinol Metab. 90:4350–4356. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Ikeda I, Ishizaka Y, Tahira T, Suzuki T,
Onda M, Sugimura T and Nagao M: Specific expression of the ret
proto-oncogene in human neuroblastoma cell lines. Oncogene.
5:1291–1296. 1990.PubMed/NCBI
|
|
101
|
Plaza Menacho I, Koster R, van der Sloot
AM, Quax WJ, Osinga J, van der Sluis T, Hollema H, Burzynski GM,
Gimm O, Buys CH, et al: RET-familial medullary thyroid
carcinomamutants Y791F and S891A activate a Src/JAK/STAT3 pathway,
independent of glial cell. Cancer Res. 65:1729–1737. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Bousquet C, Lasfargues C, Chalabi M,
Billah SM, Susini C, Vezzosi D, Caron P and Pyronnet S: Clinical
review: Current scientific rationale for the use of somatostatin
analogs and mTOR inhibitors in neuroendocrine tumor therapy. J Clin
Endocrinol Metab. 97:727–737. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Duran I, Kortmansky J, Singh D, Hirte H,
Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, et al: A phase II
clinical and pharmacodynamic study of temsirolimus in advanced
neuroendocrine carcinomas. Br J Cancer. 95:1148–1154. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Valentino JD, Li J, Zaytseva YY, Mustain
WC, Elliott VA, Kim JT, Harris JW, Campbell K, Weiss H, Wang C, et
al: Cotargeting the PI3K and RAS pathways for the treatment of
neuroendocrine tumors. Clin Cancer Res. 20:1212–1222. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Lankat-Buttgereit B, Horsch D, Barth P,
Arnold R, Blöcker S and Göke R: Effects of the tyrosine kinase
inhibitor imatinib on neuroendocrine tumor cell growth. Digestion.
71:131–140. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Perkins J, Boland P, Cohen SJ, Olszanski
AJ, Zhou Y, Engstrom P and Astsaturov I: Successful imatinib
therapy for neuroendocrine carcinoma with activating Kit mutation:
A case study. J Natl Compr Canc Netw. 6:847–852. 2014. View Article : Google Scholar
|
|
107
|
Samlowski WE, Moon J, Tuthill RJ, Heinrich
MC, Balzer-Haas NS, Merl SA, DeConti RC, Thompson JA, Witter MT,
Flaherty LE and Sondak VK: A phase II trial of imatinib mesylate in
merkel cell carcinoma (neuroendocrine carcinoma of the skin): A
Southwest Oncology Group study (S0331). Am J Clin Oncol.
33:495–499. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
de Groot JW, Zonnenberg BA, van
Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ and Voest EE: A
phase II trial of imatinib therapy for metastatic medullary thyroid
carcinoma. J Clin Endocrinol Metab. 92:3466–3469. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Lawrence B, Gustafsson BI, Kidd M and
Modlin I: New pharmacologic therapies for gastroenteropancreatic
neuroendocrine tumors. Gastroenterol Clin North Am. 39:615–628.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Fjallskog ML, Lejonklou MH, Oberg KE,
Eriksson BK and Janson ET: Expression of molecular targets for
tyrosine kinase receptor antagonists in malignant endocrine
pancreatic tumors. Clin Cancer Res. 9:1469–1473. 2003.PubMed/NCBI
|
|
111
|
Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA
and Chen H: Overexpression of the NOTCH1 intracellular domain
inhibits cell proliferation and alters the neuroendocrine phenotype
of medullary thyroid cancer cells. J Biol Chem. 281:39819–39830.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Salazar R, Chris Verslype C, Baudin E,
Libutti SK, Yao JC, Buzzoni R, Antonuzzo L, Hubner R,
García-Carbonero R, Custodio AB, et al: Phase II studies of BEZ235
in patients with advanced pancreatic neuroendocrine tumors (pNET).
J Clin Oncol. 33(15 suppl): S41022015.
|
|
113
|
Vandamme T, Beyens M, de Beeck KO, Dogan
F, van Koetsveld PM, Pauwels P, Mortier G, Vangestel C, de Herder
W, Van Camp G, et al: Long-term acquired everolimus resistance in
pancreatic neuroendocrine tumours can be overcome with novel
PI3K-AKT-mTOR inhibitors. Br J Cancer. 114:650–658. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Sippel RS, Carpenter JE, Kunnimalaiyaan M
and Chen H: The role of human achaete-scute homolog-1 in medullary
thyroid cancer cells. Surgery. 134:866–871. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Kappes A, Vaccaro A, Kunnimalaiyaan M and
Chen H: ZM336372, a Raf-1 activator, inhibits growth of
pheochromocytoma cells. Surg Res. 133:42–45. 2006. View Article : Google Scholar
|
|
116
|
Greco A, Borrello MG, Miranda C,
Degl'Innocenti D and Pierotti MA: Molecular pathology of
differentiated thyroid cancer. Q J Nucl Med Mol Imaging.
53:440–543. 2009.PubMed/NCBI
|
|
117
|
Bergers G, Javaherian K, Lo KM, Folkman J
and Hanahan D: Effects of angiogenesis inhibitors on multistage
carcinogenesis in mice. Science. 284:808–812. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Parangi S, O'Reilly M, Christofori G,
Holmgren L, Grosfeld J, Folkman J and Hanahan D: Antiangiogenic
therapy of transgenic mice impairs de novo tumor growth. Proc Natl
Acad Sci USA. 93:pp. 2002–2007. 1996; View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Yashiro T, Fulton N, Hara H, Yasuda K,
Montag A, Yashiro N, Straus F II, Ito K, Aiyoshi Y and Kaplan EL:
Comparison of mutations of ras oncogene in human pancreatic
exocrine and endocrine tumors. Surgery. 114:758–763.
1993.PubMed/NCBI
|
|
120
|
Yoshimoto K, Iwahana H, Fukuda A, Sano T,
Saito S and Itakura M: Role of p53 mutations in endocrine
tumorigenesis: Mutation detection by polymerase chain
reaction-single strand conformation polymorphism. Cancer Res.
52:5061–5064. 1992.PubMed/NCBI
|
|
121
|
Zhang HY, Rumilla KM, Jin L, Nakamura N,
Stilling GA, Ruebel KH, Hobday TJ, Erlichman C, Erickson LA and
Lloyd RV: Association of DNA methylation and epigenetic
inactivation of RASSF1A and beta-catenin with metastasis in small
bowel carcinoid tumors. Endocrine. 30:299–306. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Rahman MM, Qian ZR, Wang EL, Yoshimoto K,
Nakasono M, Sultana R, Yoshida T, Hayashi T, Haba R, Ishida M, et
al: DNA methyltransferases 1, 3a and 3b overexpression and clinical
significance in gastroenteropancreatic neuroendocrine tumors. Hum
Pathol. 41:1069–1078. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
How-Kit A, Dejeux E, Dousset B, Renault V,
Baudry M, Terris B and Tost J: DNA methylation profiles distinguish
different subtypes of gastroenteropancreatic neuroendocrine tumors.
Epigenomics. 7:1245–1258. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Jiao Y, Shi C, Edil BH, de Wilde RF,
Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA,
et al: DAXX/ATRX, MEN1 and mTOR pathway genes are frequently
altered in pancreatic neuroendocrine tumors. Science.
331:1199–1203. 2001. View Article : Google Scholar
|
|
125
|
Feng Z, Wang L, Sun Y, Jiang Z, Domsic J,
An C, Xing B, Tian J, Liu X, Metz DC, et al: Menin and Daxx
interact to suppress neuroendocrine tumors through epigenetic
control of the membrane metallo-endopeptidase. Cancer Res.
77:401–411. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Gurung B, Feng Z, Iwamoto DV, Thiel A, Jin
G, Fan CM, Ng JM, Curran T and Hua X: Menin epigenetically
represses Hedgehog signaling in MEN1 tumor syndrome. Cancer Res.
73:2650–2658. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Kim H, Lee JE, Cho EJ, Liu JO and Youn HD:
Menin, a tumor suppressor represses JunD-mediated transcriptional
activity by association with an mSin3A-histone deacetylase complex.
Cancer Res. 63:6135–6139. 2003.PubMed/NCBI
|
|
128
|
Hughes CM, Rozenblatt-Rosen O, Milne TA,
Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS,
Bhattacharjee A, Biondi CA, et al: Menin associates with a
trithorax family histone methyltransferase complex and with the
hoxc8 locus. Mol Cell. 13:587–597. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Yokoyama A, Wang Z, Wysocka J, Sanyal M,
Aufiero DJ, Kitabayashi I, Herr W and Cleary ML: Leukemia
proto-oncoprotein MLL forms a SET1-like histone methyltransferase
complex with menin to regulate Hox gene expression. Mol Cell Biol.
24:5639–5649. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Cives M, Simone V, Rizzo FM and Silvestris
F: NETs: Organ-related epigenetic derangements and potential
clinical applications. Oncotarget. 7:57414–57429. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Agarwal SK, Guru SC, Heppner C, Erdos MR,
Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS,
Spiegel AM, et al: Menin interacts with the AP1 transcription
factor JunD and represses JunD-activated transcription. Cell.
96:143–152. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Agarwal SK, Kennedy PA, Scacheri PC,
Novotny EA, Hickman AB, Cerrato A, Rice TS, Moore JB, Rao S, Ji Y,
et al: Menin molecular interactions: Insights into normal functions
and tumorigenesis. Horm Metab Res. 37:369–374. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Stalberg P, Grimfjärd P, Santesson M, Zhou
Y, Lindberg D, Gobl A, Oberg K, Westin G, Rastad J, Wang S, et al:
Transfection of the multiple endocrine neoplasia type 1 gene to a
human endocrine pancreatic tumor cell line inhibits cell growth and
affects expression of JunD, delta-like protein 1/preadipocyte
factor-1, proliferating cell nuclear antigen and QM/Jif-1. J Clin
Endocrinol Metab. 89:2326–2337. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Stefanoli M, La Rosa S, Sahnane N,
Romualdi C, Pastorino R, Marando A, Capella C, Sessa F and Furlan
D: Prognostic relevance of aberrant DNA methylation in g1 and g2
pancreatic neuroendocrine tumors. Neuroendocrinology. 100:26–34.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Fernandez-Cuesta L, Peifer M, Lu X, Sun R,
Ozretić L, Seidal D, Zander T, Leenders F, George J, Müller C, et
al: Frequent mutations in chromatin-remodelling genes in pulmonary
carcinoids. Nat Commun. 5:35182014. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Scarpa A, Chang DK, Nones K, Corbo V,
Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, et
al: Whole-genome landscape of pancreatic neuroendocrine tumours.
Nature. 543:65–71. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Boora GK, Kanwar R, Kulkarni AA, Pleticha
J, Ames M, Schroth G, Beutler AS and Banck MS: Exome-level
comparison of primary well-differentiated neuroendocrine tumors and
their cell lines. Cancer Genet. 208:374–381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Kim JT, Li J, Jang ER, Gulhati P, Rychahou
PG, Napier DL, Wang C, Weiss HL, Lee EY, Anthony L, et al:
Deregulation of Wnt/β-catenin signaling through genetic or
epigenetic alterations in human neuroendocrine tumors.
Carcinogenesis. 34:953–961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Roldo C, Missiaglia E, Hagan JP, Falconi
M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A and
Croce CM: MicroRNA expression abnormalities in pancreatic endocrine
and acinar tumors are associated with distinctive pathologic
features and clinical behavior. J Clin Oncol. 24:4677–4684. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Ruebel K, Leontovich AA, Stilling GA,
Zhang S, Righi A, Jin L and Lloyd RV: MicroRNA expression in ileal
carcinoid tumors: Downregulation of microRNA-133a with tumor
progression. Mod Pathol. 23:367–375. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Li SC, Essaghir A, Martijn C, Lloyd RV,
Demoulin JB, Oberg K and Giandomenico V: Global microRNA profiling
of well-differentiated small intestinal neuroendocrine tumors. Mod
Pathol. 26:685–696. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Døssing KB, Binderup T, Kaczkowski B,
Jacobsen A, Rossing M, Winther O, Federspiel B, Knigge U, Kjær A
and Friis-Hansen L: Down-regulation of miR-129-5p and the let-7
family in neuroendocrine tumors and metastases leads to
up-regulation of their targets Egr1 G3bp1 Hmga2 and Bach1. Genes
(Basel). 6:1–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Louwerens JK, Schaberg A and Bosman FT:
Neuroendocrine cells in cystic mucinous tumours of the ovary.
Histopathology. 7:389–398. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Pagani A, Macrí L, Rosolen A, Toffolatti
L, Stella A and Bussolati G: Neuroendocrine differentiation in
Ewing's sarcomas and primitive neuroectodermal tumors revealed by
reverse transcriptase-polymerase chain reaction of chromogranin
mRNA. Nucl Med Mol Imaging. 7:36–43. 1998.
|
|
145
|
Raymond E, Dahan L, Raoul JL, Bang YJ,
Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A,
et al: Sunitinib malate for the treatment of pancreatic
neuroendocrine tumors. N Engl J Med. 364:501–513. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Mohamed A, Romano D, Saveanu A, Roche C,
Albertelli M, Barbieri F, Brue T, Niccoli P, Delpero JR, Garcia S,
et al: Anti-proliferative and anti-secretory effects of everolimus
on human pancreatic neuroendocrine tumors primary cultures: Is
there any benefit from combination with somatostatin analogs?
Oncotarget. 8:41044–41063. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Zitzmann K, Rüden Jv, Brand S, Göke B,
Lichtl J, Spöttl G and Auernhammer CJ: Compensatory activation of
Akt in response to mTOR and Raf inhibitors-a rationale for
dual-targeted therapy approaches in neuroendocrine tumor disease.
Cancer Lett. 295:100–109. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Eichhorn PJ, Gili M, Scaltriti M, Serra V,
Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards
R, et al: Phosphatidylinositol 3-kinase hyperactivation results in
lapatinib resistance that is reversed by the
mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer
Res. 68:9221–9230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Fisseler-Eckhoff A and Demes M:
Neuroendocrine tumors of the lung cancers. Cancers Basel.
4:777–798. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Banerjee J, Papu John AM and Schuller HM:
Regulation of nonsmall-cell lung cancer stem cell like cells by
neurotransmitters and opioid peptides. Int J Cancer. 137:2815–2824.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Feng L, Wu JB and Yi FM: Isolation and
phenotypic characterization of cancer stem-like side population
cells in colon cancer. Mol Med Rep. 13:3531–3536. 2015. View Article : Google Scholar
|
|
152
|
Jaffee IM, Rahmani M, Singhal MG and
Younes M: Expression of the intestinal transcription factor CDX2 in
carcinoid tumors is a marker of midgut origin. Arch Pathol Lab Med.
130:1522–1526. 2006.PubMed/NCBI
|
|
153
|
Pelosi G, Bresaola E, Bogina G, Pasini F,
Rodella S, Castelli P, Iacono C, Serio G and Zamboni G: Endocrine
tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections
is an independent predictor for malignancy: A comparative study
with proliferating-cell nuclear antigen and progesterone receptor
protein immunostaining, mitotic index and other clinicopathologic
variables. Hum Pathol. 27:1124–1134. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Clarke MR, Baker EE, Weyant RJ, Hill L and
Carty SE: Proliferative activity in pancreatic endocrine tumors:
Association with function, metastases and survival. Endocr Pathol.
8:181–187. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Ekeblad S, Skogseid B, Dunder K, Oberg K
and Eriksson B: Prognostic factors and survival in 324 patients
with pancreatic endocrine tumor treated at a single institution.
Clin Cancer Res. 14:7798–7803. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Le Roith D, Shiloach J, Roth J and Lesniak
MA: Evolutionary origins of vertebrate hormones: Substances similar
to mammalian insulins are native to unicellular eukaryotes. Proc
Natl Acad Sci USA. 77:pp. 6184–6188. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Granberg D, Wilander E, Oberg K and
Skogseid B: Prognostic markers in patients with typical bronchial
carcinoid tumors. J Clin Endocrinol Metab. 85:3425–3430. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Diebold AE, Boudreaux JP, Wang YZ, Anthony
LB, Uhlhorn AP, Ryan P, Mamikunian P, Mamikunian G and Woltering
EA: Neurokinin A levels predict survival in patients with stage IV
well differentiated small bowel neuroendocrine neoplasms. Surgery.
152:1172–1176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Detjen KM, Rieke S, Deters A, Schulz P,
Rexin A, Vollmer S, Hauff P, Wiedenmann B, Pavel M and Scholz A:
Angiopoietin-2 promotes disease progression of neuroendocrine
tumors. Clin Cancer Res. 16:420–429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Vinik AI, Anthony L, Boudreaux JP, Go VL,
O'Dorisio TM, Ruszniewski P and Woltering EA: Neuroendocrine
tumors: A critical appraisal of management strategies. Pancreas.
39:801–818. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Kvols LK and Woltering EA: Role of
somatostatin analogs in the clinical management of
non-neuroendocrine solid tumors. Anticancer Drugs. 17:601–608.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Narayanan S and Kunz P: Role of
somatostatin analogues in the treatment of neuroendocrine tumors. J
Natl Compr Canc Netw. 13:109–117. 2015. View Article : Google Scholar : PubMed/NCBI
|
